Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

Background The use of immune checkpoint inhibitors (ICIs) has become standard therapy in
many tumor sites. The aim of this study is to systematically review the literature to determine …

Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for
patients with many advanced malignancies, only 15–60% of patients respond, leaving a …

Lung cancer is the leading cause of cancer death in Canada and a significant cause of
morbidity for patients and their loved ones. There have been rapid advances in preventing …

Importance Whether immune-related adverse events (irAEs) indicate drug activity in patients
treated with immune checkpoint inhibitors remains unknown. Objective To investigate the …

Importance Immune-related adverse events (irAEs) arising from immune checkpoint inhibitor
(ICI) cancer therapy may potentially predict improved outcomes. Objective To evaluate the …

Background A number of studies have reported an association between the occurrence of
immune-related adverse events (irAEs) and clinical efficacy in patients undergoing treatment …

Abstract Anti-programmed death-1 (anti-PD-1) immunotherapy reinvigorates CD8 T cell
responses in patients with cancer but PD-1 is also expressed by other immune cells …

Introduction In 2018, durvalumab was approved by the US Food and Drug Administration as
consolidation immunotherapy for patients with stage III NSCLC after definitive …

Purpose: Unleashing the immune system by PD-1 and/or CTLA-4 blockade can cause
severe immune-related toxicity necessitating immunosuppressive treatment. Whether …